title: Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.
abstract: Human serum albumin (HSA) nanoparticles represent promising drug carrier systems. Binding of cytostatics to HSA nanoparticles may diminish their toxicity, optimise their body distribution and/or may overcome multidrug resistance. In the present study, doxorubicin-loaded HSA nanoparticle preparations were prepared. Doxorubicin was loaded to the HSA nanoparticles either by adsorption to the nanoparticles' surfaces or by incorporation into the particle matrix. Both loading strategies resulted in HSA nanoparticles of a size range between 150nm and 500nm with a loading efficiency of 70-95%. The influence on cell viability of the resulting nanoparticles was investigated in two different neuroblastoma cell lines. The anti-cancer effects of the drug-loaded nanoparticles were increased in comparison to doxorubicin solution. Based on these result a standard protocol for the preparation of doxorubicin-loaded HSA nanoparticles for further antitumoural studies was established.
authors.affiliation: Institute of Pharmaceutical Technology, Biocenter Niederursel, Johann Wolfgang Goethe-University, Max-von-Laue-Strasse 9, D-60438 Frankfurt/Main, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Dreis
authors.forename: F
authors.initials: F
authors.lastname: Rothweiler
authors.forename: M
authors.initials: M
authors.lastname: Michaelis
authors.forename: J
authors.initials: J
authors.lastname: Cinatl
authors.forename: J
authors.initials: J
authors.lastname: Kreuter
authors.forename: K
authors.initials: K
authors.lastname: Langer
mesh_terms: D000327:Adsorption; D000903:Antibiotics, Antineoplastic / Q000737:chemistry* / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000737:chemistry* / Q000494:pharmacology; D004337:Drug Carriers; D004339:Drug Compounding; D006801:Humans; D020128:Inhibitory Concentration 50; D053758:Nanoparticles; D009447:Neuroblastoma / Q000473:pathology; D010316:Particle Size; D012709:Serum Albumin / Q000737:chemistry*; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D012709:Serum Albumin; D004317:Doxorubicin